Dexcom, Inc.: FDA filings under this applicant name
FDA lists 25 510(k) clearances under the applicant name “Dexcom, Inc.” (first 2018, latest 2026), plus 2 PMA and 3 De Novo decisions, across 10 product codes in 1 review panel. Median 510(k) review time under this name: 71 days. Since 2017 the median was 71 days, against 86 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2018 | 2 | 74 |
| 2019 | 4 | 58 |
| 2020 | 2 | 138 |
| 2021 | 2 | 365 |
| 2022 | 2 | 222 |
| 2023 | 2 | 20 |
| 2024 | 3 | 59 |
| 2025 | 3 | 75 |
| 2026 | 5 | 40 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Dexcom, Inc. took a median 71 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 86 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| QBJ | Integrated Continuous Glucose Monitoring System, Factory Calibrated | 15 | 14 |
| QDK | Integrated Continuous Glucose Monitoring System For Non-Intensive Diabetes Management | 4 | 4 |
| MDS | Sensor, Glucose, Invasive | 2 | 0 |
| SAF | Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter | 2 | 2 |
| SBH | Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter | 2 | 2 |
| PHV | Continuous Glucose Monitor Retrospective Data Analysis Software | 1 | 0 |
| PJT | Continuous Glucose Monitor Secondary Display | 1 | 0 |
| QDL | Integrated Continuous Glucose Monitoring System For Professional Retrospective Use | 1 | 1 |
| QII | Integrated Continuous Glucose Monitoring System For Professional Directed Retrospective Or Real-Time Use | 1 | 1 |
| QRX | Continuous Glucose Monitor Informed Insulin Dose Calculator | 1 | 1 |
Review panels
- Clinical Chemistry (30)
Most recent Dexcom, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K262472 | Stelo Glucose Biosensor System | SBH | 2026-08-11 | 25 |
| K260935 | Stelo Glucose Biosensor System | SBH | 2026-06-12 | 84 |
| K261402 | Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System | QBJ | 2026-06-08 | 40 |
| K261359 | Stelo Glucose Biosensor System | SAF | 2026-05-21 | 27 |
| K253737 | Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System | QBJ | 2026-02-03 | 71 |
| K253710 | Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System | QBJ | 2025-12-17 | 23 |
| K252818 | Dexcom Smart Basal | QRX | 2025-11-18 | 75 |
| K243214 | Dexcom G7 15 Day Continuous Glucose Monitoring System | QBJ | 2025-04-09 | 188 |
| K240902 | Dexcom G7 Continuous Glucose Monitoring System | QBJ | 2024-04-23 | 21 |
| K234070 | Stelo Glucose Biosensor System | SAF | 2024-03-05 | 74 |
15 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN170088 | De Novo | Integrated Continuous Glucose Monitoring System, Factory Calibrated | 2018-03-27 |
| DEN140038 | De Novo | Continuous Glucose Monitor Secondary Display | 2015-01-23 |
| DEN140016 | De Novo | Continuous Glucose Monitor Retrospective Data Analysis Software | 2014-08-19 |
| P120005 | PMA | DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM | 2012-10-05 |
| P050012 | PMA | DEXCOM STS CONTINOUS MONITORS | 2006-03-24 |
Recalls
29 product recalls in 11 recall events; 18 initiated in the last five years. Most recent: 2026-05-27.
1 product recall in 1 recall event filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: Cardinal Health Inc. (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Dexcom, Inc. is the lead sponsor of 28 device studies on ClinicalTrials.gov (5 active or recruiting). Most recent:
- NCT07681024: Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW) (Not yet recruiting, started 2026-06-15)
- NCT07603284: Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia (Active not recruiting, started 2025-11-24)
- NCT06601166: CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin (Active not recruiting, started 2024-08-15)
- NCT06483945: Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) (Active not recruiting, started 2024-02-28)
- NCT07681375: Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor (Active not recruiting, started 2023-04-11)
SEC filings
DEXCOM INC (DXCM): EDGAR filings, CIK 1093557. An SEC registrant with the same name, matched by name only.
Frequently asked questions
How many FDA 510(k) clearances are listed under Dexcom, Inc.?
FDA lists 25 510(k) clearances under the applicant name “Dexcom, Inc.” (first 2018, latest 2026), plus 2 PMA and 3 De Novo decisions, across 10 product codes in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Dexcom, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Dexcom, Inc. is 71 days. Since 2017: 71 days, versus 86 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Dexcom, Inc.?
The most frequent FDA product codes under this applicant name are QBJ (Integrated Continuous Glucose Monitoring System, Factory Calibrated, 15); QDK (Integrated Continuous Glucose Monitoring System For Non-Intensive Diabetes Management, 4); MDS (Sensor, Glucose, Invasive, 2).
Next steps
- See all 25 Dexcom, Inc. clearances with predicates and recalls
- Run predicate analysis for product code QBJ, Dexcom, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant name shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.